Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mindray Reports Preliminary 2008 Results
Based on the expected full year revenue range, fourth quarter 2008 revenue grew 76% to 87% year-over-year despite a challenging global operating environment that included volatile foreign exchange
Based on the expected full year revenue range, fourth quarter 2008 revenue grew 76% to 87% year-over-year despite a challenging global operating environment that included volatile foreign exchange
Sinclair received an immediate payment of $3.1 million in cash in place of future royalties that it would have received under the existing agreement. This payment is equivalent
The advisors also recommended that the drug be available under a risk evaluation and mitigation strategy. If approved, Sabril would be the first and only drug approved in
Kolltan has also appointed Michael Schmertzler as its new CEO and director, and Yaron Hadari as vice president of research. Joseph Schlessinger, co-founder, chief scientist and a director
The milestone payment is triggered by the recent FDA approval of Prism’s new drug application (NDA) for Nexterone (amiodarone HCl) injection, a patent-protected, cosolvent free formulation of the
Mr Buehler is currently senior vice president of global markets and chief marketing officer of Alcon Laboratories, a subsidiary of Alcon. In this capacity, he is responsible for
Midwest Dental is a dental management company headquartered in Mondovi, Wisconsin. Under the terms of this multi-year agreement, OralDNA will provide diagnostic laboratory testing to Midwest Dental to
According to Synosia Therapeutics, the proceeds will be used to fund the ongoing development of its emerging portfolio of Phase II clinical programs. The financing was led by
In preclinical models, the calcium release-activated calcium modulator inhibitors discovered by Synta potently and selectively inhibited the secretion of pro-inflammatory factors such as TNF-alpha and IL-2, with minimal
The company is currently enrolling patients in three separate protocols: two are randomized, controlled studies of patients with ACLF (acute-on-chronic liver failure) or FHF (fulminant hepatic failure). Continuous